Hair Repigmentation Associated With the Use of Brentuximab

A case was reported where a patient experienced hair repigmentation while undergoing treatment with brentuximab vedotin, an antibody-drug conjugate used for treating refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. This was notable as no prior reports had documented changes in hair pigmentation associated with brentuximab, despite its known adverse effects, which included neutropenia, peripheral sensory neuropathy, and others. This observation suggested a potential new side effect of brentuximab that warranted further investigation.